Clinical Trial Update: Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating proton radiotherapy in combination with tremelimumab and durvalumab for intermediate-to-advanced hepatocellular carcinoma (BCL…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Chang Gung Memorial Hospital | Conditions: HCC - Hepatocellular Carcinoma, Durvalumab | Phase 2 | Status: RECRUITING